Mark Coleman, Director at Axsome Therapeutics, Inc. (AXSM), sold 15,000 shares at $105.47 ($1.6M) on 2025-05-27, disclosed to the SEC on 2025-05-29.
Scheduled sale ($1.6M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $105.47 | 3,750 | $396K | 25.2% |
| 2 | $105.47 | 3,750 | $396K | 25.2% |
| 3 | $103.43 | 3,750 | $388K | 24.8% |
| 4 | $103.43 | 3,750 | $388K | 24.8% |
| Total | $104.45 avg | 15,000 | $1.6M | 100% |
| Filing → |
| AXSM | SELL | 2026-02-27 | $4.0M | — | Filing → |
| AXSM | BUY | 2025-09-09 | $263K | — | Filing → |
| AXSM | SELL | 2025-05-20 | $322K | — | Filing → |